U.S. regulators delay decision on Roche SMA drug risdiplam to Aug. 24

U.S. regulators delayed a decision on Roche's spinal muscular atrophy drug risdiplam, the Swiss drugmaker said on Tuesday, after the company submitted more data in February on the medicine against the genetic muscle-wasting disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news